Newsroom

Patient Navigation in Immuno-Oncology


(AJMC.org) BEING DIAGNOSED WITH CANCER is often the scariest news a patient will hear in his or her lifetime. In addition to the physical toll of the disease itself, there are numerous other factors associated ...

Cooling Down ICER? Five Questions to Consider


(ACCCBuzz) Jan 25, 2017 – Although the value-based reimbursement train has definitely left the station and is picking up speed, those in the oncology community continue to grapple with the thorny ...

Scientists Discover Why Some Cancers May Not Respond To Immunotherapy


(UCLA) Feb 6, 2017 - UCLA scientists have discovered that people with cancers containing genetic mutations JAK1 or JAK2, which are known to prevent tumors from recognizing or receiving signals from T cells to stop growing, will have little or no benefit from the immunotherapy drug pembrolizumab....

Opdivo Is Approved for Urothelial Carcinoma Subset


(CureToday.com) Feb 2, 2017 - The U.S. Food and Drug Administration (FDA) granted Opdivo (nivolumab) an accelerated approval for patients who have locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy. The approval is based on findings from a phase 2 CheckMate-275 study. ...

FDA Accepts Two sBLAs for Merck’s KEYTRUDA® (pembrolizumab) for Locally Advanced or Metastatic Urothelial Cancer in Cisplatin-Ineligible First-Line and Second-Line Post-Platinum Failure Treatment Settings


(Merck) Feb 3, 2017 - Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental Biologics License Applications (sBLAs) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with locally advanced or metastatic ...

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) in Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer


(Yahoo! Finance) Feb 2, 2017 - Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo injection, for intravenous use for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemoth...

Effect of CD3 on the efficacy of TCR gene therapy in vivo.


Related Articles Effect of CD3 on the efficacy of TCR gene therapy in vivo. J Clin Oncol. 2011 May 20;29(15_suppl):e13047 Authors: King JW, Ahmadi M, Xue S, Voisine C, Holler A, Waxman J, Morris E, Stauss H Abstract e13047 Background: T cell receptor (TCR) gene transfer is an efficient ...